A first-in-human trial of GBR 310 in healthy adult volunteers

Trial Profile

A first-in-human trial of GBR 310 in healthy adult volunteers

Planning
Phase of Trial: Phase I

Latest Information Update: 03 May 2017

At a glance

  • Drugs Omalizumab (Primary)
  • Indications Allergic asthma; Urticaria
  • Focus First in man; Pharmacokinetics
  • Sponsors Glenmark Pharmaceuticals Ltd
  • Most Recent Events

    • 03 May 2017 New trial record
    • 25 Apr 2017 According to a Glenmark Pharmaceuticals Ltd. media release, the US FDA has cleared the Investigational New Drug (IND) application to initiate this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top